Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated
in the laboratory to stimulate the immune system in different ways and stop cancer cells from
growing. Rituximab and fludarabine may also prevent the body from making an immune response
against the laboratory-treated white blood cells that are put back into the body.
Interleukin-2 may help the laboratory-treated white blood cells stay in the body longer.
Giving cellular adoptive immunotherapy together with rituximab, fludarabine, and
interleukin-2 may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects of cellular adoptive immunotherapy
in treating patients with relapsed or refractory follicular non-Hodgkin's lymphoma.